Study type: Human research · Status: Verified against declared source

MOTS-c: A promising mitochondrial-derived chemical sequence for therapeutic exploitation.

Frontiers in endocrinology · 2023

Study scale: Insulin resistance can lead to a decrease in the number and the abnormal morphology of mitochondria in tissue cells, which in turn hinders the synthesis of ATP (18).

Abstract only: Open source record

Product or molecular entity relationships

MOTS-c: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c) is a mitochondrial-derived peptide composed of 16 amino acids encoded by the 12S rRNA region of the mitochondrial genome.

Scale or participants

Insulin resistance can lead to a decrease in the number and the abnormal morphology of mitochondria in tissue cells, which in turn hinders the synthesis of ATP (18).

Key findings

Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c) is a mitochondrial-derived peptide composed of 16 amino acids encoded by the 12S rRNA region of the mitochondrial genome.

Limitations and uncertainty

Originally, MOTS-c was identified in the process of genetic and pharmacological screening of metabolic regulation in human cells (21).

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.